Sentences with phrase «vaccine candidates»
"Vaccine candidates" refers to potential vaccines that are in the testing or development phase. They are being studied to determine their effectiveness, safety, and ability to protect against a specific disease before they are considered for widespread use. Full definition
This new mouse model should be useful for comparative assessments of the large range of vaccine candidates now being designed.
sciencemediacentre.org
Scientists have many promising malaria vaccine candidates in the works, and for the first time one has reached advanced human trials.
It is the first malaria vaccine candidate to have made it as far as a phase 3 trial.
In order to move forward they made pioneering technological breakthroughs as well, all of which have resulted in the most promising vaccine candidate against malaria to date.
We also work with partners to develop tools and processes to evaluate vaccine candidates.
Several vaccine candidates exist, but human studies have only recently begun.
The genome sequence provides a fast track approach to finding vaccine candidates for a disease that had frustrated researchers for decades.
The authors offer research strategies that might yield more protective vaccine candidates.
Eventually, he adds, the group hopes to use an improved forecast to help decide which vaccine candidates to push ahead with.
These proteins can be comparatively tested to identify the most promising vaccine candidates, and to understand how the parasite interacts with the human host and cause disease.
As the Global HIV Vaccine Product Manager for the US Army, Dr. Ake advances the development of HIV vaccine candidates in preclinical and early clinical studies.
The Walter Reed Army Institute of Research (WRAIR) announces a Cooperative Research and Development Agreement for the development of a Zika vaccine candidate with Sanofi Pasteur, the vaccines... Read More
Time / Date: Tuesday, November 5, 2013, 3:30 p.m. * Location: Room 105, Claxton Building, 1122 Volunteer Blvd. Speaker: Dr. Clemente Aguilar, NIMBioS postdoctoral fellow Topic: Computational characterization of GPI - anchored proteins in Trypanosoma cruzi and their potential use as vaccine candidates Abstract: The plasma membrane of the causative agent of Chagas» disease, the parasite Trypanosoma cruzi, is covered with a dense, protective surface coat.
The HVTN's mission is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV infections globally.
Other Ebola vaccine candidates use vector viruses to ferry a single Ebola protein, a surface antigen, to prime the immune system.
This is achieved by testing vaccine candidates in preclinical models.
An Ebola vaccine candidate developed by GlaxoSmithKline and the National Institutes of Health effectively jump - starts the immune system with few side effects, researchers report January 28 in the New England Journal of Medicine.
Nanotheraputics for Antibiotic Resistent Emerging Bacterial pathogens (NAREB) European Research Infrastructures for Poverty Related Diseases (EURIPED) Biomarkers for enhanced vaccines immunosafety (BioVacSafe) European network of vaccine research and development TRANSVAC Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (TBVAC2020)
EVI is now embarking on vaccine candidates for other diseases of poverty in line with its wider mandate.
In order to efficiently evaluate the newly designed vaccine candidates before testing them in clinical trials there is a need for development of reliable preclinical models.
The researchers» next steps will be to conduct longer - term studies in combination with other vaccine candidates, hone in on what areas of gp120 the antibodies are binding to and determine how they can increase the antibodies» effectiveness at neutralizing HIV.
In addition, Dr. Polonis has been the project lead for development of HIV - 1 envelope subunit vaccine candidates from multiple subtypes in efforts to find an Env protein that will elicit protective responses.
«The rapid advancement of Zika vaccine candidates into clinical trials reflects the uniquely focused and effective collaboration among scientists in the field to address this important global problem,» said Barouch.
The overall aim of this project is to determine the functional significance of antibody targeted cellular and complement responses to a novel pediatric malaria vaccine candidate antigen, PfSEA - 1.
Research & Development IAVI worked with the Japanese biotech company DNAVEC, based in Tsukuba City, to jointly develop an AIDS vaccine candidate based on its novel Sendai vector technology.
«Six years ago we began using these samples to identify novel vaccine candidates and now it's coming full circle.
For infectious diseases, proteins displayed on the surface of pathogens are good vaccine candidates because vaccine - elicited antibodies can destroy or disable the pathogen.
Our priority vaccine candidates include dengue, norovirus, hand, foot & mouth disease, chikungunya and polio.
The cAd3 - EBOZ vaccine candidate was co-developed by NIAID's Vaccine Research Center and GlaxoSmithKline.
In the study, Moderna's Zika mRNA vaccine was evaluated in addition to a live - attenuated vaccine candidate developed by the University of Texas Medical Branch (UTMB).
These new preclinical studies provide support for advancing the Ad26 / MVA prime - boost vaccine candidate into clinical development.
«New Zika vaccine candidate protects mice and monkeys with a single dose: Results from study highlight the promise of mRNA - based vaccines and therapies.»
MHRP's expansion of research activities into Mozambique provides scientists the opportunity to test future vaccine candidates against the predominant HIV subtype (C) circulating in this part of the world.
The vaccine is planned for use in a phase 1 clinical trial in Japan and is the only whole - virus Ebola vaccine candidate under development.
Vaccine research will also benefit immediately from the discovery, since scientists can already now test the effectiveness of different vaccine candidates at preventing PfEMP1 from binding ECPR.
«We have shown that our mutants (versions of the bacteria) are safe vaccine candidates as our detailed analyses showed no sign of damage to bodily tissues in the vaccinated animals.»